Brian Posner Purchases 2,500 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Brian Posner purchased 2,500 shares of Dyne Therapeutics stock in a transaction dated Wednesday, May 20th. The stock was bought at an average price of $17.12 per share, for a total transaction of $42,800.00. Following the completion of the purchase, the director owned 18,000 shares in the company, valued at $308,160. This represents a 16.13% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Dyne Therapeutics Price Performance

NASDAQ:DYN opened at $17.37 on Friday. The firm’s 50 day simple moving average is $18.28 and its 200 day simple moving average is $18.39. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. Dyne Therapeutics, Inc. has a one year low of $8.06 and a one year high of $25.00. The company has a market cap of $2.87 billion, a PE ratio of -5.39 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same quarter last year, the company earned ($1.05) EPS. On average, research analysts anticipate that Dyne Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. raised its holdings in Dyne Therapeutics by 523.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock worth $343,085,000 after purchasing an additional 14,727,667 shares during the last quarter. Vanguard Group Inc. raised its holdings in Dyne Therapeutics by 14.9% during the 4th quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company’s stock worth $219,376,000 after purchasing an additional 1,455,151 shares during the last quarter. State Street Corp raised its holdings in Dyne Therapeutics by 27.0% during the 4th quarter. State Street Corp now owns 6,692,745 shares of the company’s stock worth $130,910,000 after purchasing an additional 1,423,828 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in Dyne Therapeutics by 45.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,172,000 shares of the company’s stock worth $101,164,000 after purchasing an additional 1,618,000 shares during the last quarter. Finally, Orbis Allan Gray Ltd bought a new position in Dyne Therapeutics during the 4th quarter worth approximately $93,926,000. Institutional investors own 96.68% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Wall Street Zen upgraded shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Sanford C. Bernstein lifted their target price on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Evercore set a $33.00 target price on shares of Dyne Therapeutics in a research report on Friday, May 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Finally, Chardan Capital reiterated a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 9th. Three analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.00.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.